

Marta Boffito

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3455063/publications.pdf>

Version: 2024-02-01

103
papers

2,880
citations

218677

26
h-index

206112

48
g-index

109
all docs

109
docs citations

109
times ranked

3810
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2021, 385, 1172-1183.	27.0	734
2	Protein Binding in Antiretroviral Therapies. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 825-835.	1.1	173
3	Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 1191-1200.	4.7	122
4	Pharmacokinetics, Efficacy, and Safety of Darunavir/Ritonavir 800/100 mg Once-Daily in Treatment-Naïve and -Experienced Patients. <i>HIV Clinical Trials</i> , 2008, 9, 418-427.	2.0	80
5	British HIV Association guidelines for the treatment of HIV-positive adults with antiretroviral therapy 2015. <i>HIV Medicine</i> , 2016, 17, s2-s104.	2.2	78
6	Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. <i>Aids</i> , 2007, 21, 1449-1455.	2.2	70
7	Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. <i>Aids</i> , 2004, 18, 1291-1297.	2.2	62
8	Increased Dolutegravir Peak Concentrations in People Living With Human Immunodeficiency Virus Aged 60 and Over, and Analysis of Sleep Quality and Cognition. <i>Clinical Infectious Diseases</i> , 2019, 68, 87-95.	5.8	49
9	Pain in people living with HIV and its association with healthcare resource use, well being and functional status. <i>Aids</i> , 2018, 32, 2697-2706.	2.2	47
10	Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2078-2088.	2.4	46
11	Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1670-1678.	3.0	42
12	Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA). <i>Journal of Infectious Diseases</i> , 2016, 213, 1013-1017.	4.0	40
13	Iatrogenic Cushing's syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies. <i>Clinical Medicine</i> , 2016, 16, 412-418.	1.9	36
14	The pharmacokinetics of HIV protease inhibitor combinations. <i>Current Opinion in Infectious Diseases</i> , 2005, 18, 1-7.	3.1	35
15	Pharmacokinetics of Once-Daily Darunavir-Ritonavir and Atazanavir-Ritonavir over 72 Hours following Drug Cessation. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4218-4223.	3.2	35
16	New Approaches to Antiretroviral Drug Delivery: Challenges and Opportunities Associated with the Use of Long-Acting Injectable Agents. <i>Drugs</i> , 2014, 74, 7-13.	10.9	35
17	Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions. <i>Annals of Internal Medicine</i> , 2022, 175, 744-746.	3.9	35
18	Cohort profile: The Pharmacokinetic and clinical Observations in PeoPle over fifty (POPPY) study. <i>International Journal of Epidemiology</i> , 2018, 47, 1391-1392e.	1.9	33

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetics of Atazanavir/Ritonavir Once Daily and Lopinavir/Ritonavir Twice and once Daily over 72 h following drug Cessation. <i>Antiviral Therapy</i> , 2008, 13, 901-907.	1.0	32
20	Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 202-206.	2.5	31
21	Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab278.	0.9	31
22	The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1027, 174-180.	2.3	29
23	Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1031-1036.	3.0	29
24	Steady-State Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir/Fosamprenavir in HIV-1-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 37, 1376-1384.	2.1	28
25	Pharmacokinetics and Safety of Etravirine Administered Once or Twice Daily After 2 Weeks Treatment With Efavirenz in Healthy Volunteers. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 222-227.	2.1	28
26	Abacavir Plasma Pharmacokinetics in the Absence and Presence of Atazanavir/Ritonavir or Lopinavir/Ritonavir and Vice Versa in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2007, 12, 825-830.	1.0	28
27	Development, Validation, and Field-Testing of an Instrument for Clinical Assessment of HIV-Associated Neuropathy and Neuropathic Pain in Resource-Restricted and Large Population Study Settings. <i>PLoS ONE</i> , 2016, 11, e0164994.	2.5	27
28	Rilpivirine long-acting for the prevention and treatment of HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 300-307.	3.8	26
29	Pharmacokinetics of Once-Daily Saquinavir/Ritonavir in HIV-Infected Subjects: Comparison with the Standard Twice-Daily Regimen. <i>Antiviral Therapy</i> , 2004, 9, 423-429.	1.0	26
30	Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum. <i>Clinical Infectious Diseases</i> , 2018, 67, 785-790.	5.8	25
31	Lack of Pharmacokinetic Drug Interaction between Tenofovir Disoproxil Fumarate and Nelfinavir Mesylate. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4386-4389.	3.2	24
32	Pharmacological impact of antiretroviral therapy on platelet function to investigate human immunodeficiency virus-associated cardiovascular risk. <i>British Journal of Pharmacology</i> , 2019, 176, 879-889.	5.4	24
33	Evaluation of a Clinic Dedicated to People Aging with HIV at Chelsea and Westminster Hospital: Results of a 10-Year Experience. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 188-197.	1.1	23
34	Evaluation of the psychometric properties of the HIV Disability Questionnaire among adults living with HIV in the United Kingdom: A cross-sectional self-report measurement study. <i>PLoS ONE</i> , 2019, 14, e0213222.	2.5	22
35	Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir and Atazanavir When Combined Once Daily in HIV Type 1-Infected Individuals Administered Different Atazanavir Doses. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 749-756.	1.1	21
36	Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals. <i>Clinical Infectious Diseases</i> , 2019, 68, 446-452.	5.8	21

#	ARTICLE	IF	CITATIONS
37	Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 64-68.	4.7	21
38	COVID-19 in patients with HIV. <i>Lancet HIV</i> , 2020, 7, e383.	4.7	19
39	Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial. <i>Vaccine</i> , 2013, 31, 5680-5686.	3.8	18
40	Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (A1468002). <i>Clinical Infectious Diseases</i> , 2017, 65, 442-452.	5.8	18
41	Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 38-42.	2.4	17
42	Practical Perspectives on the Use of Tipranavir in Combination With Other Medications: Lessons Learned From Pharmacokinetic Studies. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 130-139.	2.0	17
43	Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. <i>Antiviral Therapy</i> , 2005, 10, 469-77.	1.0	16
44	Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?. <i>Journal of the International AIDS Society</i> , 2019, 22, e25372.	3.0	15
45	Associations Between Widespread Pain and Sleep Quality in People With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 106-112.	2.1	15
46	Weight gain stopping/switch rules for antiretroviral clinical trials. <i>Aids</i> , 2021, 35, S183-S188.	2.2	15
47	Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?. <i>Journal of the International AIDS Society</i> , 2014, 17, 19583.	3.0	14
48	Feasibility randomized-controlled trial of online acceptance and commitment therapy for painful peripheral neuropathy in people living with HIV: The OPEN study. <i>European Journal of Pain</i> , 2021, 25, 1493-1507.	2.8	14
49	Strengths and Challenges of Various Models of Geriatric Consultation for Older Adults Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2022, 74, 1101-1106.	5.8	14
50	Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. <i>Antiviral Therapy</i> , 2008, 13, 901-7.	1.0	14
51	Host determinants of antiretroviral drug activity. <i>Current Opinion in Infectious Diseases</i> , 2005, 18, 543-549.	3.1	13
52	Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1911-1915.	3.0	13
53	Multimodality assessment of sleep outcomes in people living with HIV performed using validated sleep questionnaires. <i>International Journal of STD and AIDS</i> , 2020, 31, 996-1003.	1.1	13
54	Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. <i>Antiviral Therapy</i> , 2005, 10, 375-92.	1.0	13

#	ARTICLE	IF	CITATIONS
55	Use of Coronary Artery Calcium Scoring to Improve Cardiovascular Risk Stratification and Guide Decisions to Start Statin Therapy in People Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 85, 98-105.	2.1	12
56	Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100%mg once daily versus twice daily. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 542-545.	3.0	10
57	Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP). <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2129-2136.	3.0	10
58	Factors associated with overweight/obesity in a cohort of people living with HIV over 50 years of age. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, , 1-3.	1.2	10
59	More evidence for worse COVID-19 outcomes in people with HIV. <i>Lancet HIV</i> ,the, 2021, 8, e661-e662.	4.7	10
60	UK guideline for the use of HIV post-exposure prophylaxis 2021. <i>HIV Medicine</i> , 2022, 23, 494-545.	2.2	10
61	Twenty years of boosting antiretroviral agents. <i>Aids</i> , 2015, 29, 2229-2233.	2.2	9
62	The predictors of pain extent in people living with HIV. <i>Aids</i> , 2020, 34, 2071-2079.	2.2	9
63	Changes in functional connectivity in people with HIV switching antiretroviral therapy. <i>Journal of NeuroVirology</i> , 2020, 26, 754-763.	2.1	9
64	Antiretroviral resistance and management after pre-exposure prophylaxis. <i>Lancet HIV</i> ,the, 2020, 7, e84.	4.7	9
65	Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 149-156.	3.0	8
66	Measurement of Retinal Vessels as a Biomarker of Cerebrovascular Aging in Older HIV-Positive Men Compared With Controls. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, 199-205.	2.1	7
67	Comorbidity indices in people with HIV and considerations for coronavirus disease 2019 outcomes. <i>Aids</i> , 2020, 34, 1795-1800.	2.2	7
68	Clinical management of ageing people living with HIV in Europe: the view of the care providers. <i>Infection</i> , 2020, 48, 497-506.	4.7	7
69	An Open-Label, Randomized Study of the Impact on Insulin Sensitivity, Lipid Profile and Vascular Inflammation by Treatment with Lopinavir/Ritonavir or Raltegravir in HIV-Negative Male Volunteers. <i>Antiviral Therapy</i> , 2017, 22, 145-151.	1.0	6
70	Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2035-2041.	3.0	6
71	The triumph of HIV treatment: another new antiretroviral. <i>Lancet</i> , The, 2017, 390, 2019-2021.	13.7	6
72	Rapid ART start in early HIV infection: Time to viral load suppression and retention in care in a London cohort. <i>HIV Medicine</i> , 2020, 21, 613-615.	2.2	6

#	ARTICLE	IF	CITATIONS
73	Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1259-1266.	3.0	6
74	The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV. <i>Journal of Virus Eradication</i> , 2021, 7, 100028.	0.5	6
75	Pharmacokinetic considerations for combining 2 protease inhibitors. <i>Aids Reader</i> , 2004, 14, 110-2, 115-6.	0.3	6
76	Effect of a Modified Saquinavir/Ritonavir Dosing Regimen with Lower Dose Lead-In Phase on QTc Interval, Pharmacokinetics, Antiviral Activity and Safety in Treatment-Na ⁺ ve HIV-1-Infected Patients. <i>Drugs in R and D</i> , 2015, 15, 141-153.	2.2	5
77	The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 653-657.	2.3	5
78	Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1041-1045.	3.0	5
79	A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz035.	0.9	5
80	Pharmacokinetic interactions of modern antiretroviral therapy. <i>Aids</i> , 2021, 35, S145-S151.	2.2	5
81	Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen. <i>Antiviral Therapy</i> , 2004, 9, 423-9.	1.0	5
82	Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV ⁺ infected patients: a population PK approach. <i>Journal of the International AIDS Society</i> , 2014, 17, 19586.	3.0	4
83	Transmitted antiretroviral drug resistance in treatment na ⁺ ve HIV-infected persons in London in 2011 to 2013. <i>Journal of the International AIDS Society</i> , 2014, 17, 19747.	3.0	4
84	Pharmacology Lessons From Chemoprophylaxis Studies. <i>Clinical Infectious Diseases</i> , 2014, 59, S52-S54.	5.8	4
85	Long-acting cabotegravir for prevention: hope versus reality. <i>Lancet HIV</i> , 2017, 4, e322-e323.	4.7	4
86	Quantification of tenofovir disoproxil fumarate and emtricitabine in generic pre-exposure prophylaxis tablets obtained from the internet. <i>International Journal of STD and AIDS</i> , 2019, 30, 765-768.	1.1	4
87	Pharmacology of Current and Investigational Human Immunodeficiency virus (HIV) Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Adults. <i>Anti-Infective Agents in Medicinal Chemistry</i> , 2007, 6, 213-221.	0.6	2
88	Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-na ⁺ ve HIV-1-infected individuals. <i>HIV Clinical Trials</i> , 2018, 19, 31-37.	2.0	2
89	Indirect Human Immunodeficiency Virus Morbidity and Mortality Due to Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021, 73, 1947-1949.	5.8	2
90	Characterization of low level viraemia in HIV-infected patients receiving boosted protease inhibitor-based antiretroviral regimens. <i>HIV Research and Clinical Practice</i> , 2019, 20, 107-110.	1.1	2

#	ARTICLE	IF	CITATIONS
91	Predictive value of HIV-related versus traditional risk factors for coronary atherosclerosis in people aging with HIV. <i>AIDS Research and Human Retroviruses</i> , 2021, , .	1.1	2
92	Can we boost enough without ritonavir?. <i>Aids Reader</i> , 2004, 14, 229-30, 233-5.	0.3	2
93	Delivering specialised care to people ageing with HIV in the UK: experience and evolution of services from 2009 to 2019. <i>Lancet HIV</i> ,the, 2022, 9, S1.	4.7	2
94	Effect of hyperbilirubinaemia on neurocognitive, renal, bone and cardiovascular markers in HIV infection treated with boosted protease inhibitors. <i>Journal of the International AIDS Society</i> , 2014, 17, 19827.	3.0	1
95	Current Considerations for Clinical Management and Care of People with HIV: Findings from the 11th Annual International HIV and Aging Workshop. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 807-820.	1.1	1
96	Prevalence, severity, and risk factors of disability among adults living with HIV accessing routine outpatient HIV care in London, United Kingdom (UK): A cross-sectional self-report study. <i>PLoS ONE</i> , 2022, 17, e0267271.	2.5	1
97	Unexpected rapid weight gain in a patient with HIV and anorexia. <i>BMJ, The</i> , 2015, 351, h5551.	6.0	0
98	OO15â€¦Establishment of a monitoring service for men who have sex with men (MSM) taking generic co-formulated tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) as pre-exposure prophylaxis (PrEP) against HIV infection. <i>Sexually Transmitted Infections</i> , 2016, 92, A6.1-A6.	1.9	0
99	Pharmacokinetics (PK) of ethinylestradiol/levonorgestrel co-administered with atazanavir/cobicistat. <i>HIV Research and Clinical Practice</i> , 2019, 20, 82-91.	1.1	0
100	Guidelines in the context of medical ethics. <i>BMJ: British Medical Journal</i> , 2019, 364, l1040.	2.3	0
101	Incidental findings in elderly people living with HIV undergoing computed tomography coronary artery calcium scoring. <i>Aids</i> , 2020, 34, 1573-1575.	2.2	0
102	Pharmacokinetics and pharmacodynamics in HAART and antibiotic therapy. <i>New Microbiologica</i> , 2007, 30, 346-9.	0.1	0
103	Editorial: Is it time to implement injectable antiretroviral treatments globally?. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 119-120.	3.8	0